全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Cytoskeleton-Associated Protein 4: Functions Beyond the Endoplasmic Reticulum in Physiology and Disease

DOI: 10.5402/2012/142313

Full-Text   Cite this paper   Add to My Lib

Abstract:

Cytoskeleton-associated protein 4 (CKAP4; also known as p63, CLIMP-63, or ERGIC-63) is a 63?kDa, reversibly palmitoylated and phosphorylated, type II transmembrane (TM) protein, originally identified as a resident of the endoplasmic reticulum (ER)/Golgi intermediate compartment (ERGIC). When localized to the ER, a major function of CKAP4 is to anchor rough ER to microtubules, organizing the overall structure of ER with respect to the microtubule network. There is also steadily accumulating evidence for diverse roles for CKAP4 localized outside the ER, including data demonstrating functionality of cell surface forms of CKAP4 in various cell types and of CKAP4 in the nucleus. We will review the recent studies that provide evidence for the existence of CKAP4 in multiple cellular compartments (i.e., ER, plasma membrane, and the nucleus) and discuss CKAP4’s role in the regulation of various physiological and pathological processes, such as interstitial cystitis, drug-induced cytotoxicity, pericullar proteolytic activity, and lung lipid homeostasis. 1. Introduction Cytoskeleton-associated protein 4 (CKAP4), also known as p63, CLIMP-63, and ERGIC-63, is a 63-kDa nonglycosylated, type II transmembrane protein that is reversibly palmitoylated during interference of intracellular protein transport and mitosis [1–5]. Hans-Peter Hauri and colleagues first identified CKAP4 in 1993 while studying morphogenesis of the endoplasmic reticulum (ER). They found CKAP4 to be a resident protein of the stable ER-Golgi intermediate compartment (ERGIC) and to show signs of being highly enriched in isolated ERGIC [2]. However, early studies following this initial discovery, used rabbit polyclonal antibodies and immunoelectron microscopy to demonstrate that CKAP4 was actually located in the rough ER where it functions as a microtubule-binding protein, anchoring the ER membranes to the microtubular cytoskeleton of epithelial cells in vivo and in vitro and maintaining the structure of the ER [2, 3, 6–8]. This ability made CKAP4 the first integral membrane protein capable of linking an organelle to microtubules and earned it the name cytoskeletal-linking membrane protein or CLIMP-63 [9]. Further investigation by mutagenesis demonstrated that the luminal segment of CKAP4 oligomerizes into α-helical complexes. These coiled-coil complexes prevent CKAP4 from being located at the nuclear envelope and mediate its specific localization in the reticular domain of the ER [9]. Currently, CKAP4 is known to also be present in the plasma membrane of vascular smooth muscle cells [10], bladder

References

[1]  D. I. Mundy and G. Warren, “Mitosis and inhibition of intracellular transport stimulate palmitoylation of a 62-kD protein,” Journal of Cell Biology, vol. 116, no. 1, pp. 135–146, 1992.
[2]  A. Schweizer, M. Ericsson, T. Bachi, G. Griffiths, and H. P. Hauri, “Characterization of a novel 63 kDa membrane protein. Implications for the organization of the ER-to-Golgi pathway,” Journal of Cell Science, vol. 104, no. 3, pp. 671–683, 1993.
[3]  A. Schweizer, J. Rohrer, H. P. Hauri, and S. Kornfeld, “Retention of p63 in an ER-Golgi intermediate compartment depends on the presence of all three of its domains and on its ability to form oligomers,” Journal of Cell Biology, vol. 126, no. 1, pp. 25–39, 1994.
[4]  A. Schweizer, J. Rohrer, P. Jeno, A. De Maio, T. G. Buchman, and H. P. Hauri, “A reversibly palmitoylated resident protein (p63) of an ER-Golgi intermediate compartment is related to a circulatory shock resuscitation protein,” Journal of Cell Science, vol. 104, no. 3, pp. 685–694, 1993.
[5]  A. Schweizer, J. Rohrer, J. W. Slot, H. J. Geuze, and S. Kornfeld, “Reassessment of the subcellular localization of p63,” Journal of Cell Science, vol. 108, no. 6, pp. 2477–2485, 1995.
[6]  D. R. C. Klopfenstein, F. Kappeler, and H. P. Hauri, “A novel direct interaction of endoplasmic reticulum with microtubules,” EMBO Journal, vol. 17, no. 21, pp. 6168–6177, 1998.
[7]  C. Vedrenne, D. R. Klopfenstein, and H. P. Hauri, “Phosphorylation controls CLIMP-63-mediated anchoring of the endoplasmic reticulum to microtubules,” Molecular Biology of the Cell, vol. 16, no. 4, pp. 1928–1937, 2005.
[8]  C. Vedrenne and H. P. Hauri, “Morphogenesis of the endoplasmic reticulum: beyond active membrane expansion,” Traffic, vol. 7, no. 6, pp. 639–646, 2006.
[9]  D. R. Klopfenstein, J. Klumperman, A. Lustig, R. A. Kammerer, V. Oorschot, and H. P. Hauri, “Subdomain-specific localization of CLIMP-63 (p63) in the endoplasmic reticulum is mediated by its luminal α-helical segment,” Journal of Cell Biology, vol. 153, no. 6, pp. 1287–1299, 2001.
[10]  T. M. Razzaq, R. Bass, D. J. Vines, F. Werner, S. A. Whawell, and V. Ellis, “Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4),” Journal of Biological Chemistry, vol. 278, no. 43, pp. 42679–42685, 2003.
[11]  T. P. Conrads, G. M. Tocci, B. L. Hood et al., “CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients,” Journal of Biological Chemistry, vol. 281, no. 49, pp. 37836–37843, 2006.
[12]  N. Gupta, Y. Manevich, A. S. Kazi, J. Q. Tao, A. B. Fisher, and S. R. Bates, “Identification and characterization of p63 (CKAP4/ERGIC-63/CLIMP-63), a surfactant protein A binding protein, on type II pneumocytes,” American Journal of Physiology, vol. 291, no. 3, pp. L436–L446, 2006.
[13]  C. A. Matika, M. Wasilewski, J. A. Arnott, and S. L. Planey, “Antiproliferative factor regulates connective tissue growth factor (CTGF/CCN2) expression in T24 bladder carcinoma cells,” Molecular Biology of the Cell, vol. 23, no. 10, pp. 1976–1985, 2012.
[14]  S. L. Planey, S. K. Keay, C. O. Zhang, and D. A. Zacharias, “Palmitoylation of cytoskeleton associated protein 4 by DHHC2 regulates antiproliferative factor-mediated signaling,” Molecular Biology of the Cell, vol. 20, no. 5, pp. 1454–1463, 2009.
[15]  H. M. Shahjee, K. R. Koch, L. Guo, C. O. Zhang, and S. K. Keay, “Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 160, 2010.
[16]  D. A. Zacharias, M. Mullen, and S. L. Planey, “Antiproliferative factor-induced changes in phosphorylation and palmitoylation of cytoskeleton-associated protein-4 regulate its nuclear translocation and DNA binding,” International Journal of Cell Biology, vol. 2012, Article ID 150918, 2012.
[17]  T. Karasawa, Q. Wang, L. L. David, and P. S. Steyger, “CLIMP-63 is a gentamicin-binding protein that is involved in drug-induced cytotoxicity,” Cell Death and Disease, vol. 1, no. 11, article e102, 2010.
[18]  A. S. Kazi, J. Q. Tao, S. I. Feinstein, L. Zhang, A. B. Fisher, and S. R. Bates, “Role of the PI3-kinase signaling pathway in trafficking of the surfactant protein A receptor P63 (CKAP4) on type II pneumocytes,” American Journal of Physiology, vol. 299, no. 6, pp. L794–L807, 2010.
[19]  C. Vinson, A. Acharya, and E. J. Taparowsky, “Deciphering B-ZIP transcription factor interactions in vitro and in vivo,” Biochimica et Biophysica Acta, vol. 1759, no. 1-2, pp. 4–12, 2006.
[20]  S. S. C. Li, “Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction,” Biochemical Journal, vol. 390, no. 3, pp. 641–653, 2005.
[21]  J. E. Buss and B. M. Sefton, “Direct identification of palmitic acid as the lipid attached to p21(ras),” Molecular and Cellular Biology, vol. 6, no. 1, pp. 116–122, 1986.
[22]  J. Zhang, S. L. Planey, C. Ceballos, S. M. Stevens, S. K. Keay, and D. A. Zacharias, “Identification of CKAP4/p63 as a major substrate of the palmitoyl acyltransferase DHHC2, a putative tumor suppressor, using a novel proteomics method,” Molecular and Cellular Proteomics, vol. 7, no. 7, pp. 1378–1388, 2008.
[23]  D. A. Mitchell, A. Vasudevan, M. E. Linder, and R. J. Deschenes, “Protein palmitoylation by a family of DHHC protein S-acyltransferases,” Journal of Lipid Research, vol. 47, no. 6, pp. 1118–1127, 2006.
[24]  T. Oyama, Y. Miyoshi, K. Koyama et al., “Isolation of a novel gene on 8p21.3-22 whose expression is reduced significantly in human colorectal cancers with liver metastasis,” Genes Chromosomes and Cancer, vol. 29, no. 1, pp. 9–15, 2000.
[25]  F. Monigatti, B. Hekking, and H. Steen, “Protein sulfation analysis-a primer,” Biochimica et Biophysica Acta, vol. 1764, no. 12, pp. 1904–1913, 2006.
[26]  K. L. Moore, “The biology and enzymology of protein tyrosine O-sulfation,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 24243–24246, 2003.
[27]  S. Bates, “P63 (CKAP4) as an SP-A receptor: implications for surfactant turnover,” Cellular Physiology and Biochemistry, vol. 25, no. 1, pp. 41–54, 2010.
[28]  S. K. Keay, Z. Szekely, T. P. Conrads et al., “An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 32, pp. 11803–11808, 2004.
[29]  J. Kim, S. K. Keay, J. D. Dimitrakov, and M. R. Freeman, “p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells,” FEBS Letters, vol. 581, no. 20, pp. 3795–3799, 2007.
[30]  H. P. Hauri and A. Schweizer, “The endoplasmic reticulum-Golgi intermediate compartment,” Current Opinion in Cell Biology, vol. 4, no. 4, pp. 600–608, 1992.
[31]  J. Lippincott-Schwartz, J. G. Donaldson, A. Schweizer et al., “Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway,” Cell, vol. 60, no. 5, pp. 821–836, 1990.
[32]  J. E. Rickard and T. E. Kreis, “CLIPs for organelle-microtubule interactions,” Trends in Cell Biology, vol. 6, no. 5, pp. 178–183, 1996.
[33]  V. Ellis and S. A. Whawell, “Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells,” Blood, vol. 90, no. 6, pp. 2312–2322, 1997.
[34]  F. Werner, T. M. Razzaq, and V. Ellis, “Tissue plasminogen activator binds to human vascular smooth muscle cells by a novel mechanism. Evidence for a reciprocal linkage between inhibition of catalytic activity and cellular binding,” Journal of Biological Chemistry, vol. 274, no. 31, pp. 21555–21561, 1999.
[35]  R. Machovich, K. Ajtai, K. Kolev, and W. G. Owen, “Myosin as cofactor and substrate in fibrinolysis,” FEBS Letters, vol. 407, no. 1, pp. 93–96, 1997.
[36]  O. Kranenburg, B. Bouma, L. M. J. Kroon-Batenburg et al., “Tissue-type plasminogen activator is a multiligand cross-β structure receptor,” Current Biology, vol. 12, no. 21, pp. 1833–1839, 2002.
[37]  T. A. Hembrough, K. R. Kralovich, L. Li, and S. L. Gonias, “Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation,” Biochemical Journal, vol. 317, no. 3, pp. 763–769, 1996.
[38]  S. R. Bates, A. S. Kazi, J. Q. Tao et al., “Role of P63 (CKAP4) in binding of surfactant protein-A to type II pneumocytes,” American Journal of Physiology, vol. 295, no. 4, pp. L658–L669, 2008.
[39]  S. Keay, M. Kleinberg, C. O. Zhang, M. K. Hise, and J. W. Warren, “Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production,” Journal of Urology, vol. 164, no. 6, pp. 2112–2118, 2000.
[40]  W. G. Deng, Y. Zhu, A. Montero, and K. K. Wu, “Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay,” Analytical Biochemistry, vol. 323, no. 1, pp. 12–18, 2003.
[41]  C. M. Van Dusen, L. Yee, L. M. McNally, and M. T. McNally, “A glycine-rich domain of hnRNP H/F promotes nucleocytoplasmic shuttling and nuclear import through an interaction with transportin 1,” Molecular and Cellular Biology, vol. 30, no. 10, pp. 2552–2562, 2010.
[42]  M. Cokol, R. Nair, and B. Rost, “Finding nuclear localization signals,” EMBO Reports, vol. 1, no. 5, pp. 411–415, 2000.
[43]  S. C. Wang and M. C. Hung, “Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors,” Clinical Cancer Research, vol. 15, no. 21, pp. 6484–6489, 2009.
[44]  M. Kumeta, S. H. Yoshimura, J. Hejna, and K. Takeyasu, “Nucleocytoplasmic shuttling of cytoskeletal proteins: molecular mechanism and biological significance,” International Journal of Cell Biology, vol. 2012, Article ID 494902, 2012.
[45]  S. Keay, C. O. Zhang, J. L. Shoenfelt, and T. C. Chai, “Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis,” Urology, vol. 61, no. 6, pp. 1278–1284, 2003.
[46]  K. R. Koch, C. O. Zhang, P. Kaczmarek et al., “The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion,” Investigational New Drugs, vol. 30, no. 5, pp. 1849–1864, 2012.
[47]  S. Keay, F. Seillier-Moiseiwitsch, C. O. Zhang, T. C. Chai, and J. Zhang, “Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or antiproliferative factor treatment,” Physiological Genomics, vol. 14, pp. 107–115, 2003.
[48]  C. O. Zhang, J. Y. Wang, K. R. Koch, and S. Keay, “Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis,” Journal of Urology, vol. 174, no. 6, pp. 2382–2387, 2005.
[49]  S. Keay, S. Leitzell, A. Ochrzcin, G. Clements, M. Zhan, and D. Johnson, “A mouse model for interstitial cystitis/painfulbladder syndrome based on APF inhibition ofbladder epithelial repair: a pilot study,” BMC Urology, vol. 12, no. 1, 17 pages, 2012.
[50]  S. R. Bates, C. Dodia, J. Q. Tao, and A. B. Fisher, “Surfactant protein-A plays an important role in lung surfactant clearance: evidence using the surfactant protein-A gene-targeted mouse,” American Journal of Physiology, vol. 294, no. 2, pp. L325–L333, 2008.
[51]  S. R. Bates, J. Q. Tao, K. Notarfrancesco, K. DeBolt, H. Shuman, and A. B. Fisher, “Effect of surfactant protein A on granular pneumocyte surfactant secretion in vitro,” American Journal of Physiology, vol. 285, no. 5, pp. L1055–L1065, 2003.
[52]  Y. Kuroki, R. J. Mason, and D. R. Voelker, “Pulmonary surfactant apoprotein A structure and modulation of surfactant secretion by rat alveolar type II cells,” Journal of Biological Chemistry, vol. 263, no. 7, pp. 3388–3394, 1988.
[53]  T. Kagawa, L. Varticovski, Y. Sai, and I. M. Arias, “Mechanism by which cAMP activates PI3-kinase and increases bile acid secretion in WIF-B9 cells,” American Journal of Physiology, vol. 283, no. 6, pp. C1655–C1666, 2002.
[54]  C. R. L. Webster and M. S. Anwer, “Role of the PI3K/PKB signaling pathway in cAMP-mediated translocation of rat liver Ntcp,” American Journal of Physiology, vol. 277, no. 6, pp. G1165–G1172, 1999.
[55]  G. Tzivion, Y. H. Shen, and J. Zhu, “14-3-3 Proteins; bringing new definitions to scaffolding,” Oncogene, vol. 20, no. 44, pp. 6331–6338, 2001.
[56]  J. Wesierska-Gadek, S. B. Hajek, B. Sarg, S. Wandl, E. Walzi, and H. Lindner, “Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells,” Biochemical Pharmacology, vol. 76, no. 11, pp. 1503–1514, 2008.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133